| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
| 16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
| 03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
| 16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 03 Jan 2022 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 27 December 2021 and 31 December 2021 | Download |
| 28 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 20 December 2021 and 24 December 2021 | Download |
| 20 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 | Download |
| 17 Dec 2021 | On business and financial situation | ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia | Download |
| 13 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 | Download |